Hops (Humulus lupulus).

Hops bitter acids and valerian valerenic acid both act as positive modulators at GABA-A receptor sites, the same channel from different binding positions. The pair has been the standard European evening formula for well over a century.

Valerenic acid modulates the GABA-A receptor at the beta subunit while hops constituents act at their own site on the same channel, so the calming effect adds. This is the oldest and most standardised hops combination in herbal practice.

Melatonin acts on circadian timing through MT1 and MT2 receptors while hops acts on GABA-A tone, two separate routes into the same evening wind-down. Formulators combine them so timing and calm are covered at once.

Passionflower flavonoids raise GABA tone and hops modulates the GABA-A channel, so the two reinforce one another at the same receptor family. The combination is long standing in evening tea and tincture blends.

Rosmarinic acid from lemon balm slows GABA transaminase and so raises available GABA, while hops modulates the receptor GABA acts on. Supply and receptor sensitivity are addressed on one pathway.

Theanine dampens glutamate signalling and raises alpha wave activity, a different lever from the GABA-A modulation hops provides. The two are combined for daytime calm without heavy sedation.

Magnesium sits in the NMDA receptor channel and also modulates GABA-A, lowering excitatory tone from a direction hops does not reach. The glycine carrier itself acts at inhibitory glycine receptors.

Hops modulates the GABA-A receptor rather than supplying the neurotransmitter, so pairing it with GABA addresses ligand and receptor sensitivity together. Oral GABA crosses poorly, which keeps this an early rather than settled pairing.

Apigenin from chamomile binds the benzodiazepine site of the GABA-A receptor while hops constituents modulate the same channel elsewhere. Two ligands on one receptor complex is why the blend is traditional.

Isolated apigenin is the chamomile flavone that binds the GABA-A benzodiazepine site, giving a defined ligand alongside the broader hops modulation. The two occupy different positions on the same receptor complex.

Honokiol and magnolol are positive modulators at GABA-A, the same receptor family hops acts on, so calming and drowsiness effects add rather than sit side by side. Formulas carrying both should account for the combined load.

Kavalactones modulate GABA-A and voltage-gated ion channels, so combining kava with hops stacks two agents on the same inhibitory pathway. This is an honest additive-effect note rather than a benefit pairing.

Red clover isoflavones and the hops prenylflavonoid 8-prenylnaringenin both bind oestrogen receptors, so their activity at that receptor adds. Blends carrying both should be regarded as one combined phytoestrogen load.

5-HTP is decarboxylated to serotonin, part of which is converted onward to melatonin in the pineal gland. Hops constituents act on GABAergic and melatonergic signalling in preclinical work. Combining them stacks two routes toward the same sleep-onset end-point, so drowsiness during the day is the practical thing to watch. The pairing is common in night-time blends and has not been tested as a combination in humans.

Tryptophan is the upstream amino acid for both serotonin and melatonin synthesis, and its entry to the brain depends on competition with other large neutral amino acids. Hops is used for the same sleep-onset window by a separate route. Formulators stack them for that reason. Additive daytime sedation is the direction to keep in view.

Glycine is an inhibitory neurotransmitter at its own receptor and also a co-agonist at NMDA receptors, and it lowers core body temperature before sleep. Hops acts through different inhibitory signalling. Both are used in the same pre-bed window, so the sedative direction adds. Neither has a combination trial behind the pairing.

Ashwagandha withanolides are studied for effects on the stress-hormone axis, while hops sits on inhibitory neurotransmission. The two are combined in evening formulas to cover both routes. Any effect from a blend cannot be assigned to either component. Read the pairing as formulation practice.

Both botanicals are handled by hepatic phase I and phase II enzymes and both have shown modest enzyme-modulating behaviour in vitro. Combining two CYP-active plant extracts makes the metabolic picture less predictable for anything else taken at the same time. A pharmacokinetic study of a hops supplement in women found measurable changes in drug-metabolising enzyme activity. Read the pairing as mechanistically plausible and untested together.

Hyperforin activates the pregnane X receptor and strongly induces CYP3A4 and P-glycoprotein, which speeds clearance of many co-ingested compounds including plant constituents. Hops prenylflavonoids are CYP substrates, so an induced state lowers their exposure. Two sedative-direction botanicals also stack on drowsiness. The induction side is textbook pharmacology and does not depend on a combination trial.

Caffeine antagonises adenosine receptors and lengthens sleep latency, the opposite direction to a sedative-class botanical taken before bed. Caffeine's half-life of several hours means an afternoon dose still overlaps an evening hops dose. Separating them by time is more useful than adjusting either amount. The opposition is established stimulant pharmacology.

Quercetin and the hops prenylflavonoids are both flavonoid-class polyphenols cleared through glucuronidation and sulfation. Co-dosing loads the same conjugation enzymes, which can raise circulating levels of whichever is the weaker competitor. The direction is plausible from established phase II biochemistry rather than measured for this pair. Neither compound reaches high systemic concentrations from ordinary doses.

Resveratrol is cleared almost entirely by glucuronidation and sulfation, the same phase II routes that limit xanthohumol exposure. Two heavily conjugated polyphenols taken together compete for the same enzyme capacity. Both are also studied for effects on metabolic markers rather than on outcomes. The interaction is mechanistic and has not been measured in humans for this pair.

Xanthohumol reaching the colon is converted by gut bacteria, including the demethylation step that yields 8-prenylnaringenin, and gut simulation work shows hops compounds shift microbial metabolism and bile acid handling. A fermentable prebiotic changes the bacterial population doing that conversion. The direction of any change in prenylflavonoid output depends on which taxa expand. This is mechanistic modelling, not a human result.

Only some people carry the bacterial capacity to convert isoxanthohumol to 8-prenylnaringenin efficiently, which is why exposure to the potent estrogenic metabolite varies so widely between individuals. Live cultures alter the colonic community that performs the conversion. Whether a given strain raises or lowers that output is not established. In vitro gastrointestinal models are where this has been examined.

EGCG and xanthohumol are both extensively glucuronidated and sulfated on first pass, which caps how much of either reaches circulation. Combined they compete for the same conjugating enzymes. Both extracts are also concentrated forms whose constituent load differs greatly from the whole plant. Concentrated catechin extracts carry their own intake ceiling and are counted separately.